Hongcheng stable cell line construction platform has two host cell systems, GS wild type and deletion type. Through transient transfection or rapid stable transformation of pool cells, it can provide milligram to gram samples to support drug-resistance research. Within 3 months, we can complete the screening from transfection to monoclonal. The whole experiment process uses commercial, chemically defined medium, with monoclonal planking and microphotograph equipment, which effectively proves the source of monoclonal, and provides stable, high-yield and quality cell lines for the development of cell culture technology. Support the establishment of main cell bank and working cell bank meeting GMP requirements, and provide seeds meeting GMP production for later clinical samples and commercial production.

The backbone members of the downstream process development team of HONGCHENG. have worked in this field for more than 10 years and accumulated rich experience, including various purification process development, process amplification, technology transfer to cGMP production, etc. Product types include recombinant protein, monoclonal antibody, bispecific antibody, fusion protein, antibody fragment, etc. It has a complete platform to support process R&D. Each purification step was optimized. Risk assessment and definition of key process parameters (PCPP). 3L scale process development, 15 / 50L scale process confirmation, 200L scale pilot production.